Table 5 Proposals for improving the acceptability of generic medicines
From: “No generics, Doctor!” The perspective of general practitioners in two French regions
N | % | 95% CI | |
|---|---|---|---|
What measures do you think could make it easier to prescribe generics and make them more acceptable? (Several possible answers) | |||
Public education and information campaigns for patients | 105 | 33.2 | 29.9–36.7 |
Identical presentation and dosage form for generics and originators | 85 | 26.9 | 23.8–30.2 |
Harmonization of communication between practitioners and pharmacists | 45 | 14.2 | 11.9–17.0 |
More information given to the patient by the physician | 44 | 13.9 | 11.6–16.6 |
More studies demonstrating the equivalence of generics and originators | 35 | 11.1 | 9.0–13.6 |
Abandonment of brand names | 33 | 10.4 | 8.4–12.9 |
Initial prescription by INN a | 30 | 9.5 | 7.6–11.8 |
Financial penalties for patients | 26 | 8.2 | 6.4–10.5 |
More transparency about the manufacturing process of generics | 24 | 7.6 | 5.9–9.8 |
More transparency about the manufacturing origins of generics | 20 | 6.3 | 4.8–8.3 |
Education and information campaigns aimed at physicians | 17 | 5.4 | 4.0–7.3 |
Harmonization of communication between general practitioners and other specialists | 12 | 3.8 | 2.6–5.5 |
Financial penalties for physicians | 5 | 1.6 | 0.9–2.8 |
Financial incentives for patients | 1 | 0.3 | 0.0–1.1 |
Financial incentives for physicians | 0 | 0 | 0 |